Ahmedabad-based Zydus Lifesciences said on Tuesday that a new drug application for its oral drug Desidustat used in treating anaemia in chronic kidney disease (CKD) patients had been accepted by the National Medical Products Administration of China (NMPA). In 2020, CMS International Development and Management Ltd, a wholly-owned subsidiary of China Medical System Holdings Ltd obtained an exclusive license for the product from Zydus. CKD involves a gradual loss of functioning of kidneys and eventually leads to kidney failure.
The approval comes a day after Sinopharm said its vaccine showed 79.34 per cent efficacy and a 99.52 per cent antibody-positive conversion rate in the interim results of the Phase III clinical trials.
The vaccination, available at 48 designated clinics in 15 districts, began on December 24, targeting certain groups of people aged between 18 and 59 years, He Zhenyu, deputy director of the centre for disease control and prevention in Wuhan, told the media in Wuhan.
A notice issued to the foreign journalists on Wednesday said they can get the Inactivated SARS-CoV-2 Vaccine, developed by Sinopharm's China National Biotec Group. Sinopharm's COVID-19 vaccine has been granted conditional market approval by China's National Medical Products Administration.
According to the WHO, countries should join the COVID-19 Vaccine Global Access Facility (COVAX Facility) by September 18 but not later than October 9 with upfront payments.
'This novel format of diplomacy -- the informal summit -- will not only facilitate bilateral communication and reduce miscalculations at the very top level of the two governments, but possibly open the space for China and India to speak in one voice on various issues of mutual concern,' note Feng Renjie and Ding Kun Lei
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances